Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | SI | P14410 | 2/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654463 | 0.95 | ALDH1A1 (0.33) | CA1CA2ALDH1A1SOAT1 | |
| SCHEMBL16809087 | 0.86 | TSHR (0.37) | TSHR | |
| SCHEMBL1471558 | 0.86 | ALDH1A1 (0.50) | CA1CA2ALDH1A1MGAMGAA | |
| SCHEMBL9749086 | 0.83 | — | — | |
| SCHEMBL1128339 | 0.83 | HDAC7 (0.37) | CA1CA2TSHR | |
| SCHEMBL16024 | 0.82 | — | — | |
| SCHEMBL654464 | 0.82 | — | — | |
| SCHEMBL7157006 | 0.80 | MEN1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL6655623 | 0.80 | — | — | |
| SCHEMBL8434353 | 0.80 | TSHR (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3249735-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING THE SAME | Mitsubishi Chemical Corporation (JP) | 2017-11-29 | — | — | EP | disclosed |
| US-9136560-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20150166520-A1 | AMIDO-SUBSTITUTED PYRIMIDINONE DERIVATIVES USEFUL FOR THE TREATMENT OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8435681-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20130095379-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | KOTATO MINORU (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20120244426-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-09-27 | — | — | US | disclosed |
| US-8043745-B2 | Non-aqueous electrolyte solution and lithium secondary battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8007938-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20110070485-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20070224514-A1 | Nonaqueous Electrolyte Solution and Lithium Secondary Battery Using Same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1744394-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166520-A1 | AMIDO-SUBSTITUTED PYRIMIDINONE DERIVATIVES USEFUL FOR THE TREATMENT OF HIV INFECTION | ARG1, ASS1, ARG2 | CA1 4870/4885CA2 4779/4885TSHR 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.